Rhythm Pharmaceuticals (RYTM) investor relations material

FDA approval and indication

• IMCIVREE (setmelanotide) received FDA approval as the first and only therapy for reducing and maintaining excess body weight in adults and children aged 4 years and older with acquired hypothalamic obesity (HO), with a broad indication not limited to tumor-related causes.

• No post-marketing commitments are required for this approval.

• The approval is based on significant clinical benefit demonstrated in the global Phase 3 TRANSCEND trial.

• IMCIVREE expands its indication beyond Bardet-Biedl syndrome and certain genetic deficiencies.

• Approximately 10,000 people in the U.S. are estimated to have acquired HO.

Clinical trial results

• The label reflects data from 142 patients, including the primary cohort, Japanese cohort, and supplemental patients.

• Setmelanotide showed a statistically significant placebo-adjusted BMI reduction of 18.4% after 52 weeks (mean -15.8% in setmelanotide arm vs +2.6% in placebo, p<0.0001).

• Patients aged 12 and older experienced a 2.3-point reduction in hunger scores versus 1.4 in placebo; hunger data is included in the label's clinical results section.

• Setmelanotide was generally well tolerated; most common adverse events included skin hyperpigmentation, nausea, vomiting, headache, and injection site reactions.

• The reduction in hunger aligns with the biology of HO and is a key burden for patients.

Safety and label details

• The label includes standard dosing, warnings, and adverse events, with a specific warning for adrenal insufficiency due to the high prevalence of hormonal deficiencies in this population.

• Recommended starting dose is 0.5 mg daily, titrated up to 3 mg daily for patients 6 years and older.

• Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.

• Serious risks include hypersensitivity, depression, suicidal ideation, acute adrenal insufficiency, and sodium imbalance in patients with central diabetes insipidus.

• Monitoring for adrenal and vasopressin insufficiency is emphasized due to the complexity of patient comorbidities.